Search results for "From ACP Journal Club"
In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia
An ACP Journal Club commentary pointed out that use of once-weekly insulin for patients with type 2 diabetes will require more cautious dose-titration algorithms and less stringent glycemic targets to avoid hypoglycemia.
https://diabetes.acponline.org/archives/2021/03/12/7.htm
12 Mar 2021
In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM
A industry-funded trial found improved glucose control in men randomized to testosterone injections, but some of its claims were exaggerated, and routine use of testosterone therapy to prevent or reverse type 2 diabetes is not recommended, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/05/14/7.htm
14 May 2021
SGLT2 inhibitors reduce all-cause mortality
A recent meta-analysis found lowered mortality risk with sodium-glucose cotransporter-2 (SGLT2) inhibitors, and an ACP Journal Club commentary added that other trials have shown beneficial effects of the drug class on kidney function in patients with type 2 diabetes.
https://diabetes.acponline.org/archives/2021/05/14/6.htm
14 May 2021
In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y
Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/06/11/9.htm
11 Jun 2021
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021
One-step screening approach detected more gestational diabetes than two-step approach but did not improve clinical outcomes
A screening approach that finds more cases of gestational diabetes without improving patient outcomes introduces considerable burden and costs to patients, clinicians, and medical systems, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/08/13/6.htm
13 Aug 2021
Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
A recent Italian trial showed that regimens with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose cotransporter 2 (SGLT2) inhibitor resulted in less hypoglycemia, but the results may not apply to patients with higher HbA1c levels, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/09/10/7.htm
10 Sep 2021
In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control
Clinicians can use the results of a recent European trial to reassure patients that good glycemic control can be achieved with either device, although real-time monitoring may be beneficial for those with more hypoglycemia issues, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/10/08/7.htm
8 Oct 2021
In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
This industry-funded trial of tirzepatide, a unimolecular dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, heralds a new era of “twincretins” in diabetes management, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/11/12/6.htm
12 Nov 2021
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Once tirzepatide is approved by the FDA, it may be a treatment option for patients with type 2 diabetes who are overweight, have high risk for atherosclerotic cardiovascular (CV) disease, and have no gastrointestinal symptoms, an ACP Journal Club summary said.
https://diabetes.acponline.org/archives/2022/03/11/7.htm
11 Mar 2022